Luke Evnin, Director at Werewolf Therapeutics, Inc. (HOWL), sold 105,565 shares at $0.44 ($43K) on 2026-06-04, disclosed to the SEC on 2026-06-08.
Scheduled sale ($43k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.44 | 20,072 | $9K | 20.5% |
| 2 | $0.40 | 24,946 | $10K | 23.2% |
| 3 | $0.40 | 60,547 | $24K | 56.3% |
| Total | $0.41 avg | 105,565 | $43K | 100% |
| Filing → |
| HOWL | SELL | 2026-06-10 | $28K | — | Filing → |
| HOWL | SELL | 2026-06-03 | $64K | — | Filing → |
| HOWL | SELL | 2026-05-29 | $66K | — | Filing → |